Table 1 Baseline characteristics of atrial fibrillation patients receiving rivaroxaban with and without anti-arrhythmic drugs before and after propensity score matching.
Characteristics | Concomitant-AAD (n = 739) | Rivaroxaban alone Unmatched (n = 1649) | P | Rivaroxaban alone Matched (n = 738) | P | |||
|---|---|---|---|---|---|---|---|---|
Age, yr, mean (SD) | 74.1 | (10.1) | 73.3 | (12.3) | 0.084 | 74.3 | (11.1) | 0.737 |
Female, no. (%) | 358 | (48.4) | 829 | (50.3) | 0.426 | 374 | (50.7) | 0.405 |
AF type | 0.109 | 0.788 | ||||||
Paroxysmal AF, no. (%) | 606 | (82.0) | 1304 | (79.1) | 601 | (81.4) | ||
Persistent AF, no. (%) | 133 | (18.0) | 345 | (20.9) | 137 | (18.6) | ||
Pre-CHF admission, no. (%) | 216 | (29.2) | 622 | (37.7) | < 0.001 | 223 | (30.2) | 0.690 |
Hypertension, no. (%) | 594 | (80.4) | 1235 | (74.9) | 0.003 | 597 | (80.9) | 0.843 |
Diabetes, no. (%) | 256 | (34.6) | 552 | (33.5) | 0.575 | 260 | (35.2) | 0.827 |
Prior major bleeding, no. (%) | 49 | (6.6) | 157 | (9.5) | 0.022 | 33 | (4.5) | 0.088 |
Prior TIA/stroke, no. (%) | 130 | (17.6) | 419 | (25.4) | < 0.001 | 131 | (17.7) | 0.946 |
Prior TIA/ Stroke/Systemic thromboembolism, no. (%) | 150 | (20.3) | 499 | (30.3) | < 0.001 | 151 | (20.5) | 0.949 |
Liver cirrhosis, no. (%) | 28 | (3.8) | 84 | (5.1) | 0.175 | 31 | (4.2) | 0.693 |
LVEF (%), mean (SD) | 60.1 | (10.3) | 60.0 | (9.8) | 0.778 | 60.0 | (9.9) | 0.791 |
eGFR, mL/mm/1.73m2, mean (SD) | 64.3 | (23.0) | 70.2 | (28.4) | < 0.001 | 66.1 | (27.5) | 0.171 |
Medication | ||||||||
ACEI / ARB, no. (%) | 455 | (61.6) | 1019 | (61.8) | 0.927 | 473 | (64.1) | 0.333 |
Beta-blocker, no. (%) | 234 | (31.7) | 548 | (33.2) | 0.479 | 265 | (35.9) | 0.088 |
Statin, no. (%) | 240 | (32.5) | 529 | (32.1) | 0.850 | 233 | (31.6) | 0.738 |
Aspirin, no. (%) | 34 | (4.6) | 66 | (4.0) | 0.508 | 31 | (4.2) | 0.800 |
Clopidogrel or brilinta, no. (%) | 28 | (3.8) | 64 | (3.9) | 1.000 | 24 | (3.2) | 0.672 |
NSAID, no. (%) | 97 | (13.1) | 224 | (13.6) | 0.795 | 89 | (12.1) | 0.583 |
